
The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has updated its recommendations for pneumococcal vaccine in high-risk adults.






